Story of Lorla

This is the entry page for the English version of the book project Story of Lorla.

Lorla is at the center of a narrative biography of a modern cancer medicine: from the scientific foundations and clinical trials to the questions that become important for patients and clinicians in everyday care.

Deutsche Version: Geschichte der Lorla

Prologue

Section I: Development

Section II: Clinical Proving Ground

  • 🔓 Chapter 3: MTD, 3+3, and Bayesian Models (Free to read)
  • 🔒 Chapter 4: The Early ALK Inhibitors – Part I (Exclusive to the Reading Circle)
  • 🔒 Chapter 5: B7461001 Phase 1 – Dose Escalation (Exclusive to the Reading Circle)
  • 🔒 Chapter 6: B7461001 Phase 1 – The Search for the RP2D (Exclusive to the Reading Circle)
  • 🔒 Chapter 7: The Early ALK Inhibitors – Part II (Exclusive to the Reading Circle)
  • 🔒 Chapter 8: The FDA/AACR Workshop (Exclusive to the Reading Circle)
  • 🔒 Chapter 9: B7461001 Phase 1 – 64 Days (Exclusive to the Reading Circle)
  • 🔒 Chapter 10: B7461001 Phase 1 – Habemus RP2D (Exclusive to the Reading Circle)
  • 🔒 Chapter 11: The Early ALK Inhibitors – Part III (Exclusive to the Reading Circle)
  • 🔒 Chapter 12: B7461001 Phase 2 – The Registration Study (Exclusive to the Reading Circle)
  • 🔒 Chapter 13: The CNS Study – Isolated CNS Progression (Exclusive to the Reading Circle)
  • 🔓 Chapter 14: Understanding Lorla’s Effects on the CNS (Free to read / Section conclusion)

Section III: Coronation with Obstacles

  • 🔓 Chapter 15: On the Road to Coronation (Free to read)
  • 🔒 Chapter 16: The Debate (Exclusive to the Reading Circle)
  • 🔒 Chapter 17: The Compromise (Exclusive to the Reading Circle)
  • 🔒 Chapter 18: The Debate over the Optimal Dose (Exclusive to the Reading Circle)
  • 🔒 Chapter 19: The Call for Coronation (Exclusive to the Reading Circle)
  • 🔒 Chapter 20: The Data Were There – The Coronation Was Not (Exclusive to the Reading Circle)
  • 🔒 Chapter 21: Concentration Makes the Difference (Exclusive to the Reading Circle)
  • 🔓 Chapter 22: The Coronation – After the 5-Year Data (Free to read / Section conclusion)

Section IV: The Cliffs of Everyday Practice

  • 🔓 Chapter 23: First Steps in Therapy Management (Free to read)
  • 🔒 Chapter 24: Patient-Oriented Therapy Management (Exclusive to the Reading Circle)
  • 🔒 Timeline (Exclusive to the Reading Circle)
  • 🔒 Chapter 25: Flexible Therapy Management (Exclusive to the Reading Circle)
  • 🔒 Price Parity (Exclusive to the Reading Circle)
  • 🔒 Chapter 27: Price Parity (Exclusive to the Reading Circle)
  • 🔓 Chapter 28: Three Strategies for Starting Therapy (Free to read / Section conclusion)

Section V: The Provisional End of the Story

Epilogue